clavulanate. We examined whether amoxicillin/clavulanate was With the advent of potent b-lactamase inhibitors, such as active in patients by measuring its effect on recovery of sulbactam and clavulanate, and carbapenems (e.g., imipenem
Resurgence of tuberculosis and outbreaks caused by multiSee the editorial response by Kernodle on pages 878 -9. ple-drug-resistant (MDR) strains of Mycobacterium tuberculosis are reminders that new drugs are still needed [1] .
b-lactam
Clinical experience with b-lactam antibiotics for tuberculoantibiotics have been largely overlooked as antituberculous sis has been minimal. A total of seven patients with tuberculosis agents. Mycobacterial cell wall [2] has been regarded as an caused by MDR strains and treated with the b-lactam antibiinsurmountable barrier to drug penetration. Mycobacterial botic -inhibitor combination amoxicillin/clavulanate have been lactamases hydrolyze many penicillins and cephalosporins [3 - reported, and four seemed to respond [13, 14] . The necessity 6]. Early work demonstrating that inhibition of M. tuberculosis of using combinations of several drugs in the treatment regimen b-lactamase improved the activity of benzylpenicillin against precludes assessment of the individual activity of amoxicillin/ M. tuberculosis [7, 8] went largely unnoticed.
clavulanate. We examined whether amoxicillin/clavulanate was With the advent of potent b-lactamase inhibitors, such as active in patients by measuring its effect on recovery of sulbactam and clavulanate, and carbapenems (e.g., imipenem
M. tuberculosis cfu from sputum of patients with smear-posiand meropenem), which are not substrate for M. tuberculosis tive pulmonary tuberculosis. b-lactamases, the activity of b-lactam drugs against M. tuberculosis in vitro was rediscovered [9 -11] . We have shown that Methods in vitro susceptibility to b-lactam antibiotics is consistent with their biochemical properties: they bind target penicillin-binding
Determination of Early Bactericidal Activity in Patients with
proteins with high affinity, they penetrate mycobacterial cell Tuberculosis wall, and b-lactamase inactivation can be circumvented [12] .
These studies were conducted in the General Clinical Research Center of the University of California San Francisco at 03-07-98 00:58:39 cida UC: CID serious underlying medical illness, such as liver failure, renal bacteria isolated. Ten patients were treated with amoxicillin/ clavulanate, 10 with ofloxacin, and 11 with isoniazid. Mitchifailure, or decompensated heart failure; (8) allergy or contraindication for use of study drug; (9) treatment for tuberculosis son's agar method was Ç0.5 -1 log 10 cfu/mL more sensitive (data shown below were calculated from these results) than during the preceding 3 months; and (10) lack of informed consent.
the NaOH method [20] , but elimination rates were virtually identical. Patients were randomized in an unblinded fashion to one of the three oral regimens, administered for 7 days: (1) amoxicil-
The MICs of isoniazid were £0.2 mg/mL for isolates from patients who were administered this drug. MICs of isolates lin/clavulanate, 1,000 mg/250 mg three times a day; (2) ofloxacin, 600 mg once daily; or (3) isoniazid, 300 mg once daily.
from patients given ofloxacin were £2 mg/mL. MICs of amoxicillin/clavulanate were 4 -8 mg/mL. Two 12-hour, overnight sputum samples were collected for quantitative culture before administration of drug to establish All three regimens reduced M. tuberculosis in sputum. Isoniazid was the most effective agent, reducing cfu over 2 days at baseline counts. Therapy was initiated and sputum was collected daily for the next 7 days. At the conclusion of the study a mean ({SD) rate of 0.60 { 0.30 log 10 cfu/mL per day, vs. 0.32 { 0.05 and 0.34 { 0.03 for ofloxacin and amoxicillin/ period, standard isoniazid/rifampin-based four-drug combination regimens were administered to patients, all of whom succlavulanate, respectively (figure 1 and table 1) (P õ .001 for isoniazid vs. amoxicillin/clavulanate; P Å .023 for isoniazid cessfully completed therapy.
vs. ofloxacin; P ú .1 for amoxicillin/clavulanate vs. ofloxacin).
The rate over 7 days of isoniazid treatment was 00.27 log 10
Quantitative Culture of Sputum Specimens cfu/mL per day, similar to published values of 00.19 to 00.25 A 2-mL portion of the sputum specimen was decontaminated by the N-acetyl-L-cysteine (NALC)/NaOH method [15] . A separate 2-mL portion was treated with either 2 mL of 0.5% NALC or 4 mL of 6.5 mM dithiothreitol (DTT) in phosphate buffer [16] . Samples were processed and quantitatively cultured as described [16, 17] onto both nonselective Middlebrook 7H10 agar (for NaOH-decontaminated samples) and Mitchison's selective Middlebrook 7H11 agar (for NaOH-treated and NALCor DTT-treated samples).
Colonies were counted after 6 weeks, and the results were expressed as log 10 cfu per mL of sputum. Differences in baseline counts among patients were adjusted for by subtracting the average of the two pretreatment days from the value for each treatment day. The mean elimination rate was calculated by linear regression. Differences among groups were analyzed for statistical significance by analysis of variance with the Bonferoni correction for multiple comparisons.
In Vitro Susceptibility Studies
Drug susceptibility was determined by either the agar dilution method [18] or the broth dilution method with a TB System (Becton Dickinson Diagnostic Instrumentation Systems, Sparks, MD) [19, 20] . Amoxicillin/clavulanate was tested by the BACTEC method (Becton Dickinson) at amoxicillin concentrations of 2, 4, and 8 mg/mL plus a fixed concentration of clavulanate at 8 mg/mL.
Results

Figure 1. Results of quantitative sputum cultures in patients with
Forty-five patients were enrolled at the two study sites: 18 pulmonary tuberculosis who received isoniazid (300 mg orally once patients at San Francisco General Hospital and 27 at the site in daily; छ), ofloxacin (600 mg orally once daily; ᭞), or amoxicillin/ Turkey. Fourteen patients were not evaluable: 9 had insufficient clavulanate (1,000 mg/250 mg orally three times daily; ᮀ) for 7 days. growth on culture, 3 were too ill to risk experimental therapy Data are mean { SE for each of the 2 pretreatment baseline days and each of the 7 treatment days. and dropped out of the study, and 2 had nontuberculous myco-/ 9c4a$$ap55 03-07-98 00:58:39 cida UC: CID log 10 cfu/mL per day [16, 21] . Rates ranging from 00.09 to this approach would be useful in demonstrating the activity of agents of unknown efficacy, e.g., b-lactam antibiotics; after a 00.25 log 10 cfu/mL per day during the first 2 days of treatment and 00.10 to 00.18 log 10 cfu/mL per day during a 2-week relationship between in vitro activity and in vivo efficacy was established for a prototype, it should be generalizable to other treatment period have been reported for rifampin, ethambutol, agents exhibiting similar activity in vitro. Results with ampicilpyrazinamide, and streptomycin [16] .
lin/sulbactam confirmed this. Thus, elimination rates of 00.34 and 00.10 log 10 cfu/mL Amoxicillin/clavulanate had early bactericidal activity per day for amoxicillin/clavulanate for the first 2 days of treatagainst M. tuberculosis in patients that was similar to that ment and days 0 -7, respectively, compare favorably to those observed for ofloxacin and other agents except isoniazid [16] . for conventional antituberculous agents other than isoniazid.
However, little reduction in counts occurred after the third day The magnitude of reduction in mycobacteria over the 7-day of amoxicillin/clavulanate therapy, for unclear reasons. The treatment was linearly related to the number of organisms presphenomenon may be somewhat independent of the drug used ent in pretreatment sputum specimens for patients receiving because for many agents greatest activity has occurred early isoniazid (P Å .02) or amoxicillin/clavulanate (P Å .03) but during therapy [16] . The effect also could be due to the fact not ofloxacin.
that b-lactam antibiotics are active only against dividing cells The reduction in mycobacterial burden with amoxicillin/claand that they do not penetrate into mammalian cells particularly vulanate was a direct drug effect. Means and standard deviawell, such that there is preferential elimination of extracellular tions for the two pretreatment days were virtually identical organisms, with a plateau due to persistence of intracellular (7.83 { 1.86 [n Å 10] and 7.96 { 1.69), with a reduction in organisms. counts occurring only after drug was administered. There was This may account for the observation that those patients with a dose response: in dose-ranging experiments three patients more cfu in sputum before treatment had a greater overall who were treated for 7 days at an amoxicillin/clavulanate dosreduction in mycobacterial burden over the 7 days of amoxicilage of 500 mg/125 mg three times a day had no reduction in lin/clavulanate treatment. Patients with smear-positive tubercucfu (0.00 { 0.03 log 10 cfu/mL per day).
losis have a large number of extracellular organisms, and as Ampicillin/sulbactam, another b-lactamase-inhibitor combithe burden of organisms increases, correspondingly more may nation that has in vitro activity against M. tuberculosis, was be accessible to drug. A phenotypic change (e.g., increased bevaluated in separate studies. Six patients were given ampicillactamase production) in cells surviving after the first few days lin/sulbactam at a dosage of 440 mg/300 mg orally twice daily could also account for the plateau in activity. Further studies for 7 days. The overall rate was 00.16 { 0.06 log 10 cfu/mL are needed to characterize this phenomenon and its therapeutic per day (r 2 Å 0.93; P õ .001), similar to that observed for implications. amoxicillin/clavulanate.
Our results lend support to the position advanced by Mitchison [22, 23] that bactericidal endpoints and rates during the early stages of therapy (i.e., sterilization of sputum cultures at Discussion 2 months or reductions in organism burden during the first few Our results are the first to demonstrate that b-lactam antibiotdays of drug treatment) in a small number of patients can ics have activity against M. tuberculosis in patients with tuberprovide extremely useful information about drug efficacy, short culosis. Amoxicillin/clavulanate was tested for three reasons:
of the ''gold standard'' of relapse-free survival. Although effi-(1) biochemical and susceptibility data predicted activity; (2) cacy studies utilizing early bactericidal activity will never reanecdotal clinical data, although inconclusive, suggested that place definitive, long-term studies (for example, pyrazinamide, it was effective; and (3) it can be administered orally. Early which is a good sterilizing agent, has relatively poor early bactericidal activity was assessed by a quantitative culture bactericidal activity), this approach is underutilized as a relamethod originally devised by Mitchison [16] to rank-order the tively rapid and efficient means of evaluating new candidates for treatment of tuberculosis. relative efficacy of antituberculous drugs. We reasoned that / 9c4a$$ap55 03-07-98 00:58:39 cida UC: CID
